Hawaii Biotech Initiates Phase I Trial for Dengue Vaccine

Hawaii Biotech, Inc. President and CEO Elliot Parks, Ph.D., announced Tuesday that the company has initiated a Phase 1 clinical study with its monovalent dengue vaccine candidate.
Earth Times